Fiserv Inc. Common Stock vs Viatris Inc — how do they compare? Fiserv Inc. Common Stock trades at $46.97 (market cap $24.50B), while Viatris Inc trades at $18.03 (market cap $20.05B). The key difference: Fiserv Inc. Common Stock is the larger of the two by market cap, and Viatris Inc pays a 2.75% dividend while Fiserv Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fiserv Inc. Common Stock for 0 Days and Viatris Inc for 57 Days on average.
| FISV | VTRS | |
|---|---|---|
Market Cap | $24.50B | $20.05B |
Volume | 3,682,634 | 8,682,135 |
Sector | Technology | Health |
52-Week High | $126.54 | $18.27 |
52-Week Low | $44.36 | $9.98 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $52.29B | $32.16B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Viatris (VTRS) trades at $17.25, down 1.65% on the day, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported a net loss of $3.51 billion for 2025, though recent quarters have consistently beaten EPS estimates. Revenue remains stable around $14.3 billion, with a dividend of $0.12 declared for September 2026. The balance sheet shows a debt-to-asset ratio of 38.74% for 2025, with positive operating cash flow of $2.32 billion.
The outlook is mixed: analyst consensus is a Buy with a $22.17 price target, indicating 28% upside, supported by strong cash generation and pipeline progress. However, persistent net losses, high P/E ratio of 236.2, and competitive pressures in the generics market pose significant risks. Investor sentiment is cautiously optimistic, driven by earnings beats and strategic approvals like WAKIX in Japan.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Fiserv, Inc. is a global provider of payments and financial services technology, offering merchant acquiring, digital commerce, and financial solutions through its Merchant Solutions and Financial Solutions segments.
Read more on FISV →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →